Summary: In 5988 patients with heart failure and an ejection fraction above 40%, empagliflozin 10 mg reduced cardiovascular death or heart failure hospitalisation compared with placebo (13.8% vs 17.1%; hazard ratio 0.79; 95% CI 0.69 to 0.90) over a median of 26.2 months, with or without diabetes. The effect was mainly on heart failure hospitalisation.
PICO Summary
| Element | Detail |
|---|---|
| Population | 5988 patients with class II to IV heart failure and an ejection fraction above 40%, with or without diabetes; double-blind, randomised, placebo-controlled trial; median follow-up 26.2 months. |
| Intervention | Empagliflozin 10 mg once daily added to usual therapy (n=2997). |
| Comparison | Placebo added to usual therapy (n=2991). |
| Outcome | Cardiovascular death or heart failure hospitalisation: 415 (13.8%) vs 511 (17.1%); HR 0.79 (95% CI 0.69 to 0.90); p<0.001, mainly related to a lower risk of heart failure hospitalisation. Total heart failure hospitalisations: 407 vs 541; HR 0.73 (95% CI 0.61 to 0.88); p<0.001. Effects appeared consistent with or without diabetes. Uncomplicated genital and urinary tract infections and hypotension were more frequent with empagliflozin. |
Expert Commentary
My verdict is positive. Heart failure with an ejection fraction above 40% has had few treatments shown to change outcomes, and in 5988 such patients empagliflozin reduced cardiovascular death or heart failure hospitalisation from 17.1% to 13.8% over a median of 26.2 months (hazard ratio 0.79; 95% CI 0.69 to 0.90). Total heart failure hospitalisations fell as well (407 against 541; hazard ratio 0.73; 95% CI 0.61 to 0.88), and the effect appeared consistent with or without diabetes. The limitation to weigh is what drove the result. The abstract states that the benefit was mainly related to fewer heart failure hospitalisations, and it gives no separate estimate for cardiovascular death, so a survival benefit should not be assumed. Uncomplicated genital and urinary tract infections and hypotension were more frequent with empagliflozin. The trial was funded by the manufacturers. Can I use this with my patients? Yes. For a patient with symptomatic heart failure and an ejection fraction above 40%, with or without diabetes, empagliflozin 10 mg is a reasonable addition to usual therapy, with the aim of keeping the patient out of hospital. I would like to see the mortality question answered in pooled analyses with the other large trial in this population.
References
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038. PMID: 34449189.

